Global non invasive cancer diagnostics and technologies market is anticipated to show lucrative growth over the forecast period owing to factor such as rising demand for minimally invasive therapeutics and diagnosis for the treatment of cancer. Moreover, increasing prevalence of cancer because of rising aging population and unhealthy lifestyle is also important factor that is fueling the growth of this market. Commercialization of non invasive cancer diagnostics and technologies is expected to grow owing to completion of human genome project (HGP) which will help in identifying chemical base pairs which make up DNA, hence opening avenues for market players. Rising awareness amongst people about the advantages of early diagnosis and treatment of cancer has led to a hike in number of people undergoing diagnosis. Furthermore, growing research and development in cancer diagnosis and treatment is another factor that is boosting the growth. Advancements in cancer detection technologies like cancer biomarkers and fluorescence in situ hybridization (FISH) technique are also expected to contribute towards the growth of this market.
The global non invasive cancer diagnostics and technologies market is segmented into type and technology. Based on type this market is further sub segmented into breast cancer, blood cancer, lung cancer and solid tumors. Breast cancer held the largest share in 2014 owing to factor such as increasing incidence of breast cancer. Moreover, rising awareness amongst people about symptoms, diagnosis and therapies about breast cancer has contributed towards the dominance of this segment. Also, government and non-government organization?s (NGO) initiatives to create awareness about breast cancer early diagnosis and treatment are also helping to grow this market. Breast cancer segment is also expected to witness lucrative growth over the coming seven years as a consequence of advancements like lumpectomy and partial mastectomy. Based on technology the market is segmented into immunochemistry, molecular diagnosis and clinical chemistry. Molecular diagnostic market held the largest share in 2014 as a consequence of various advantages associated to it. These advantages include high precision of diagnosis such as high specificity, high sensitivity, and rapid turnaround time.
This report aims to provide a comprehensive presentation of the global market for Non-Invasive Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Invasive Cancer Diagnostics. This report contains market size and forecasts of Non-Invasive Cancer Diagnostics in global, including the following market information:
Global Non-Invasive Cancer Diagnostics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Non-Invasive Cancer Diagnostics market was valued at US$ 111670 million in 2022 and is projected to reach US$ 144320 million by 2029, at a CAGR of 3.7% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
CTCs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-Invasive Cancer Diagnostics include Gen-Probe Inc, Digene Corporation, Quest Diagnostics Inc, Cancer, Genetics Inc, BIOVIEW Inc, AVIVA Biosciences Corporation, Laboratory Corporation of America Holdings (LabCorp), A&G Pharmaceutical and Affymetrix Inc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Invasive Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Invasive Cancer Diagnostics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Non-Invasive Cancer Diagnostics Market Segment Percentages, by Type, 2022 (%)
CTCs
CTNAS
Exosomes
Global Non-Invasive Cancer Diagnostics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Non-Invasive Cancer Diagnostics Market Segment Percentages, by Application, 2022 (%)
Blood
Urine
Saliva
Global Non-Invasive Cancer Diagnostics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Non-Invasive Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Invasive Cancer Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Invasive Cancer Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gen-Probe Inc
Digene Corporation
Quest Diagnostics Inc
Cancer, Genetics Inc
BIOVIEW Inc
AVIVA Biosciences Corporation
Laboratory Corporation of America Holdings (LabCorp)
A&G Pharmaceutical
Affymetrix Inc
Precision Therapeutics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Invasive Cancer Diagnostics, market overview.
Chapter 2: Global Non-Invasive Cancer Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Non-Invasive Cancer Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Invasive Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Invasive Cancer Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Invasive Cancer Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Invasive Cancer Diagnostics Overall Market Size
2.1 Global Non-Invasive Cancer Diagnostics Market Size: 2022 VS 2029
2.2 Global Non-Invasive Cancer Diagnostics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Invasive Cancer Diagnostics Players in Global Market
3.2 Top Global Non-Invasive Cancer Diagnostics Companies Ranked by Revenue
3.3 Global Non-Invasive Cancer Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Non-Invasive Cancer Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Invasive Cancer Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Invasive Cancer Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Non-Invasive Cancer Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Invasive Cancer Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-Invasive Cancer Diagnostics Market Size Markets, 2022 & 2029
4.1.2 CTCs
4.1.3 CTNAS
4.1.4 Exosomes
4.2 By Type - Global Non-Invasive Cancer Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Non-Invasive Cancer Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Non-Invasive Cancer Diagnostics Revenue, 2024-2029
4.2.3 By Type - Global Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Invasive Cancer Diagnostics Market Size, 2022 & 2029
5.1.2 Blood
5.1.3 Urine
5.1.4 Saliva
5.2 By Application - Global Non-Invasive Cancer Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Non-Invasive Cancer Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Non-Invasive Cancer Diagnostics Revenue, 2024-2029
5.2.3 By Application - Global Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Non-Invasive Cancer Diagnostics Market Size, 2022 & 2029
6.2 By Region - Global Non-Invasive Cancer Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Non-Invasive Cancer Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Non-Invasive Cancer Diagnostics Revenue, 2024-2029
6.2.3 By Region - Global Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Non-Invasive Cancer Diagnostics Revenue, 2018-2029
6.3.2 US Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.3.3 Canada Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.3.4 Mexico Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Non-Invasive Cancer Diagnostics Revenue, 2018-2029
6.4.2 Germany Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.4.3 France Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.4.4 U.K. Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.4.5 Italy Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.4.6 Russia Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.4.7 Nordic Countries Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.4.8 Benelux Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Non-Invasive Cancer Diagnostics Revenue, 2018-2029
6.5.2 China Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.5.3 Japan Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.5.4 South Korea Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.5.5 Southeast Asia Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.5.6 India Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Non-Invasive Cancer Diagnostics Revenue, 2018-2029
6.6.2 Brazil Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.6.3 Argentina Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Invasive Cancer Diagnostics Revenue, 2018-2029
6.7.2 Turkey Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.7.3 Israel Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.7.4 Saudi Arabia Non-Invasive Cancer Diagnostics Market Size, 2018-2029
6.7.5 UAE Non-Invasive Cancer Diagnostics Market Size, 2018-2029
7 Non-Invasive Cancer Diagnostics Companies Profiles
7.1 Gen-Probe Inc
7.1.1 Gen-Probe Inc Company Summary
7.1.2 Gen-Probe Inc Business Overview
7.1.3 Gen-Probe Inc Non-Invasive Cancer Diagnostics Major Product Offerings
7.1.4 Gen-Probe Inc Non-Invasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.1.5 Gen-Probe Inc Key News & Latest Developments
7.2 Digene Corporation
7.2.1 Digene Corporation Company Summary
7.2.2 Digene Corporation Business Overview
7.2.3 Digene Corporation Non-Invasive Cancer Diagnostics Major Product Offerings
7.2.4 Digene Corporation Non-Invasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Digene Corporation Key News & Latest Developments
7.3 Quest Diagnostics Inc
7.3.1 Quest Diagnostics Inc Company Summary
7.3.2 Quest Diagnostics Inc Business Overview
7.3.3 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Major Product Offerings
7.3.4 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.3.5 Quest Diagnostics Inc Key News & Latest Developments
7.4 Cancer, Genetics Inc
7.4.1 Cancer, Genetics Inc Company Summary
7.4.2 Cancer, Genetics Inc Business Overview
7.4.3 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Major Product Offerings
7.4.4 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Cancer, Genetics Inc Key News & Latest Developments
7.5 BIOVIEW Inc
7.5.1 BIOVIEW Inc Company Summary
7.5.2 BIOVIEW Inc Business Overview
7.5.3 BIOVIEW Inc Non-Invasive Cancer Diagnostics Major Product Offerings
7.5.4 BIOVIEW Inc Non-Invasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.5.5 BIOVIEW Inc Key News & Latest Developments
7.6 AVIVA Biosciences Corporation
7.6.1 AVIVA Biosciences Corporation Company Summary
7.6.2 AVIVA Biosciences Corporation Business Overview
7.6.3 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Major Product Offerings
7.6.4 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.6.5 AVIVA Biosciences Corporation Key News & Latest Developments
7.7 Laboratory Corporation of America Holdings (LabCorp)
7.7.1 Laboratory Corporation of America Holdings (LabCorp) Company Summary
7.7.2 Laboratory Corporation of America Holdings (LabCorp) Business Overview
7.7.3 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Major Product Offerings
7.7.4 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.7.5 Laboratory Corporation of America Holdings (LabCorp) Key News & Latest Developments
7.8 A&G Pharmaceutical
7.8.1 A&G Pharmaceutical Company Summary
7.8.2 A&G Pharmaceutical Business Overview
7.8.3 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Major Product Offerings
7.8.4 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.8.5 A&G Pharmaceutical Key News & Latest Developments
7.9 Affymetrix Inc
7.9.1 Affymetrix Inc Company Summary
7.9.2 Affymetrix Inc Business Overview
7.9.3 Affymetrix Inc Non-Invasive Cancer Diagnostics Major Product Offerings
7.9.4 Affymetrix Inc Non-Invasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.9.5 Affymetrix Inc Key News & Latest Developments
7.10 Precision Therapeutics
7.10.1 Precision Therapeutics Company Summary
7.10.2 Precision Therapeutics Business Overview
7.10.3 Precision Therapeutics Non-Invasive Cancer Diagnostics Major Product Offerings
7.10.4 Precision Therapeutics Non-Invasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.10.5 Precision Therapeutics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Invasive Cancer Diagnostics Market Opportunities & Trends in Global Market
Table 2. Non-Invasive Cancer Diagnostics Market Drivers in Global Market
Table 3. Non-Invasive Cancer Diagnostics Market Restraints in Global Market
Table 4. Key Players of Non-Invasive Cancer Diagnostics in Global Market
Table 5. Top Non-Invasive Cancer Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Invasive Cancer Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Invasive Cancer Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Invasive Cancer Diagnostics Product Type
Table 9. List of Global Tier 1 Non-Invasive Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Invasive Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Non-Invasive Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Invasive Cancer Diagnostics Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Non-Invasive Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Invasive Cancer Diagnostics Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Non-Invasive Cancer Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Invasive Cancer Diagnostics Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 30. Gen-Probe Inc Company Summary
Table 31. Gen-Probe Inc Non-Invasive Cancer Diagnostics Product Offerings
Table 32. Gen-Probe Inc Non-Invasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 33. Gen-Probe Inc Key News & Latest Developments
Table 34. Digene Corporation Company Summary
Table 35. Digene Corporation Non-Invasive Cancer Diagnostics Product Offerings
Table 36. Digene Corporation Non-Invasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 37. Digene Corporation Key News & Latest Developments
Table 38. Quest Diagnostics Inc Company Summary
Table 39. Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Product Offerings
Table 40. Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 41. Quest Diagnostics Inc Key News & Latest Developments
Table 42. Cancer, Genetics Inc Company Summary
Table 43. Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Product Offerings
Table 44. Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 45. Cancer, Genetics Inc Key News & Latest Developments
Table 46. BIOVIEW Inc Company Summary
Table 47. BIOVIEW Inc Non-Invasive Cancer Diagnostics Product Offerings
Table 48. BIOVIEW Inc Non-Invasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 49. BIOVIEW Inc Key News & Latest Developments
Table 50. AVIVA Biosciences Corporation Company Summary
Table 51. AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Product Offerings
Table 52. AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 53. AVIVA Biosciences Corporation Key News & Latest Developments
Table 54. Laboratory Corporation of America Holdings (LabCorp) Company Summary
Table 55. Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Product Offerings
Table 56. Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 57. Laboratory Corporation of America Holdings (LabCorp) Key News & Latest Developments
Table 58. A&G Pharmaceutical Company Summary
Table 59. A&G Pharmaceutical Non-Invasive Cancer Diagnostics Product Offerings
Table 60. A&G Pharmaceutical Non-Invasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 61. A&G Pharmaceutical Key News & Latest Developments
Table 62. Affymetrix Inc Company Summary
Table 63. Affymetrix Inc Non-Invasive Cancer Diagnostics Product Offerings
Table 64. Affymetrix Inc Non-Invasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 65. Affymetrix Inc Key News & Latest Developments
Table 66. Precision Therapeutics Company Summary
Table 67. Precision Therapeutics Non-Invasive Cancer Diagnostics Product Offerings
Table 68. Precision Therapeutics Non-Invasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 69. Precision Therapeutics Key News & Latest Developments
List of Figures
Figure 1. Non-Invasive Cancer Diagnostics Segment by Type in 2022
Figure 2. Non-Invasive Cancer Diagnostics Segment by Application in 2022
Figure 3. Global Non-Invasive Cancer Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Invasive Cancer Diagnostics Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Non-Invasive Cancer Diagnostics Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Invasive Cancer Diagnostics Revenue in 2022
Figure 8. By Type - Global Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 9. By Application - Global Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 10. By Type - Global Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 12. By Application - Global Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 14. By Region - Global Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 15. By Country - North America Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 16. US Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 20. Germany Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 21. France Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 28. China Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 32. India Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 34. Brazil Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Non-Invasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 37. Turkey Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Non-Invasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 41. Gen-Probe Inc Non-Invasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Digene Corporation Non-Invasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. BIOVIEW Inc Non-Invasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. A&G Pharmaceutical Non-Invasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Affymetrix Inc Non-Invasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Precision Therapeutics Non-Invasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
